Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

A quantitative analysis of statistical power identifies obesity end points for improved in vivo preclinical study design

International Journal of Obesity volume 41, pages 1306–1309 (2017)Cite this article

Subjects

Abstract

The design of well-powered in vivo preclinical studies is a key element in building the knowledge of disease physiology for the purpose of identifying and effectively testing potential antiobesity drug targets. However, as a result of the complexity of the obese phenotype, there is limited understanding of the variability within and between study animals of macroscopic end points such as food intake and body composition. This, combined with limitations inherent in the measurement of certain end points, presents challenges to study design that can have significant consequences for an antiobesity program. Here, we analyze a large, longitudinal study of mouse food intake and body composition during diet perturbation to quantify the variability and interaction of the key metabolic end points. To demonstrate how conclusions can change as a function of study size, we show that a simulated preclinical study properly powered for one end point may lead to false conclusions based on secondary end points. We then propose the guidelines for end point selection and study size estimation under different conditions to facilitate proper power calculation for a more successful in vivo study design.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. Lancet 2011; 377: 557–567.

    Article  Google Scholar 

  2. Dietrich MO, Horvath TL . Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons. Nat Rev Drug Discov 2012; 11: 675–691.

    Article  CAS  Google Scholar 

  3. Tsang R, Colley L, Lynd LD . Inadequate statistical power to detect clinically significant differences in adverse event rates in randomized controlled trials. J Clin Epidemiol 2009; 62: 609–616.

    Article  Google Scholar 

  4. Ravussin Y, Gutman R, LeDuc CA, Leibel RL . Estimating energy expenditure in mice using an energy balance technique. Int J Obes 2013; 37: 399–403.

    Article  CAS  Google Scholar 

  5. Morton GJ, Thatcher BS, Reidelberger RD, Ogimoto K, Wolden-Hanson T, Baskin DG et al. Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats. Am J Physiol Endocrinol Metab 2012; 302: E134–E144.

    Article  CAS  Google Scholar 

  6. Wagner JD, Zhang L, Kavanagh K, Ward GM, Chin JE, Hadcock JR et al. A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys. J Pharmacol Exp Ther 2010; 335: 103–113.

    Article  CAS  Google Scholar 

  7. Ravussin Y, LeDuc CA, Watanabe K, Mueller BR, Skowronski A, Rosenbaum M et al. Effects of chronic leptin infusion on subsequent body weight and composition in mice: can body weight set point be reset? Mol Metab 2014; 3: 432–440.

    Article  CAS  Google Scholar 

  8. Guo J, Hall KD . Estimating the continuous-time dynamics of energy and fat metabolism in mice. PLoS Comput Biol 2009; 5: e1000511.

    Article  Google Scholar 

  9. Guo J, Hall KD . Predicting changes of body weight, body fat, energy expenditure and metabolic fuel selection in C57BL/6 mice. PLoS One 2011; 6: e15961.

    Article  CAS  Google Scholar 

  10. Lin B, Koibuchi N, Hasegawa Y, Sueta D, Toyama K, Uekawa K et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol 2014; 13: 2215–2215.

    Google Scholar 

  11. Doyon C, Denis RG, Baraboi ED, Samson P, Lalonde J, Deshaies Y et al. Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese zucker rats. Diabetes 2006; 55: 3403–3410.

    Article  CAS  Google Scholar 

  12. Guo J, Jou W, Gavrilova O, Hall KD . Persistent diet-induced obesity in male C57BL/6 mice resulting from temporary obesigenic diets. PLoS One 2009; 4: e5370–e5379.

    Article  Google Scholar 

  13. Stevens J, Truesdale KP, McClain JE, Cai J . The definition of weight maintenance. Int J Obes 2006; 30: 391–399.

    Article  CAS  Google Scholar 

  14. Wang JL, Chiou JM, Mueller HG . Review of functional data analysis. Annu Rev Stat Appl 2015; 3: 257–295.

    Article  Google Scholar 

  15. Senn SS . Statistical Issues in Drug Development. John Wiley & Sons: Chichester, UK, 2008.

    Google Scholar 

Download references

Acknowledgements

Pfizer Inc. supported the research of JS, WCT and CJM. Data used in this research were from a study sponsored by the Intramural Research Program of the NIH, NIDDK.

Author information

Author notes

  1. W C Thompson

    Present address: 3Current address: SAS Institute, Cary, NC, USA.,

Authors and Affiliations

  1. Internal Medicine Research Unit, Pfizer Inc., Cambridge, MA, USA

    J Selimkhanov, W C Thompson & C J Musante

  2. Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA

    J Guo & K D Hall

Authors
  1. J Selimkhanov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W C Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K D Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C J Musante
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C J Musante.

Ethics declarations

Competing interests

JS, WCT and CJM were employees of Pfizer Inc. during this study. The remaining authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on International Journal of Obesity website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Selimkhanov, J., Thompson, W., Guo, J. et al. A quantitative analysis of statistical power identifies obesity end points for improved in vivo preclinical study design. Int J Obes 41, 1306–1309 (2017). https://doi.org/10.1038/ijo.2017.93

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2017.93

This article is cited by

Search

Advanced search

Quick links